Last reviewed · How we verify
Anti-SARS-CoV-2
Anti-SARS-CoV-2 is a Small molecule drug developed by Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran. It is currently in Phase 2 development. Also known as: Purified F(ab')2 Fragments of Equine hyperimmune Serum, F(ab')2 Fragments, Passive Immunotherapy, Equine F(ab')2 Fragments.
Researchers have conducted observational studies on the effectiveness of mRNA Covid-19 vaccines, specifically Moderna mRNA-1273 and BNT162b2, in patients with various conditions, including cancer, Covid-19, vaccine response, rheumatoid arthritis, and systemic lupus erythematosus. The studies, such as the "ANTICOV" observational study, aim to monitor the effects of the COVID-19 vaccine on these patient groups.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti-SARS-CoV-2 |
|---|---|
| Also known as | Purified F(ab')2 Fragments of Equine hyperimmune Serum, F(ab')2 Fragments, Passive Immunotherapy, Equine F(ab')2 Fragments, Hyperimmune Equine Serum |
| Sponsor | Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- COVID-19
- Asymptomatic COVID-19
- Diarrhoea
- Nausea
- Fatigue
- Myalgia
- Headache
- Blood pressure increased
- Cough
- Pyrexia
- Blood glucose increased
- Arthralgia
Key clinical trials
- Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
- An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. (PHASE4)
- COVID-19 and Cancer Patients
- Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen (NA)
- Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers (PHASE1)
- Study Testing Convalescent Plasma vs Best Supportive Care (PHASE1)
- Outpatient Treatment With Anti-Coronavirus Immunoglobulin (PHASE3)
- Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-SARS-CoV-2 CI brief — competitive landscape report
- Anti-SARS-CoV-2 updates RSS · CI watch RSS
- Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran portfolio CI
Frequently asked questions about Anti-SARS-CoV-2
What is Anti-SARS-CoV-2?
Who makes Anti-SARS-CoV-2?
Is Anti-SARS-CoV-2 also known as anything else?
What development phase is Anti-SARS-CoV-2 in?
What are the side effects of Anti-SARS-CoV-2?
Related
- Manufacturer: Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran — full pipeline
- Also known as: Purified F(ab')2 Fragments of Equine hyperimmune Serum, F(ab')2 Fragments, Passive Immunotherapy, Equine F(ab')2 Fragments, Hyperimmune Equine Serum
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing